Advertisement

FDA Approves New Drug for Crohn Disease and Ulcerative Colitis — Physician’s First Watch

Medical News |
May 22, 2014

FDA Approves New Drug for Crohn Disease and Ulcerative Colitis

By Kristin J. Kelley

The FDA has approved vedolizumab, an injectable monoclonal antibody, to treat adults with moderate-to-severe Crohn disease and ulcerative colitis (UC). The drug, marketed as Entyvio, is indicated for patients who have not responded well to one or more conventional therapies (e.g., corticosteroids, immunomodulators, tumor necrosis factor inhibitors).

Vedolizumab, an integrin receptor antagonist, provides an alternative to natalizumab, another option for patients who can't tolerate standard treatments. Natalizumab, a drug with a similar mechanism of action, may increase the risk for progressive multifocal leukoencephalopathy, a brain infection. The FDA hasn't found an increased PML risk with vedolizumab, but patients should be monitored for concerning neurologic signs or symptoms.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement